US Stock MarketDetailed Quotes
ALLO Allogene Therapeutics
- 2.555
- -0.085-3.22%
Close Oct 31 16:00 ET
- 2.555
- 0.0000.00%
Post 16:03 ET
534.28MMarket Cap-1606P/E (TTM)
2.730High2.540Low2.21MVolume2.640Open2.640Pre Close5.82MTurnover1.46%Turnover RatioLossP/E (Static)209.11MShares5.77552wk High1.04P/B386.60MFloat Cap2.01052wk Low--Dividend TTM151.31MShs Float55.000Historical High--Div YieldTTM7.20%Amplitude2.010Historical Low2.636Avg Price1Lot Size
About Allogene Therapeutics Company
Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, David M. Tanen, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.
Company Profile
SymbolALLO
Company NameAllogene Therapeutics
Listing DateOct 11, 2018
Issue Price18.00
Founded2017
CEODr. David D. Chang, M.D.,PhD
MarketNASDAQ
Employees233
Fiscal Year Ends12-31
Address210 East Grand Avenue
CitySouth San Francisco
ProvinceCalifornia
CountryUnited States of America
Zip Code94080-4811
Phone1-650-457-2700
Websitehttp://www.allogene.com
Company Executives
- Name
- Position
- Salary
- Dr. David D. Chang, M.D.,PhD
- Director, Chief Executive Officer and President
- 14.06M
- Timothy L. Moore
- Executive Vice President and Chief Technical Officer
- 5.80M
- Dr. Zachary Roberts, M.D.,PhD
- Executive Vice President, Research and Development and Chief Medical Officer
- 8.13M
- Geoffrey M. Parker
- Executive Vice President and Chief Financial Officer
- --
- Annie Yoshiyama
- Principal Accounting Officer, Senior Vice President and Corporate Controller
- --
- Earl Douglas
- Senior Vice President, General Counsel, Compliance Officer and Corporate Secretary
- --
- Dr. Arie S. Belldegrun, F.A.C.S.,M.D.
- Executive Chairman of the Board
- 9.36M
- Joshua A. Kazam
- Director
- 684.49K
- David Bonderman
- Lead Independent Director
- --
- Dr. Owen N. Witte, M.D.
- Independent Director
- 510.00K
- Deborah M. Messemer
- Independent Director
- 495.00K
- Dr. Franz Bernard Humer, PhD
- Independent Director
- 585.00K
- Dr. Vicki L. Sato, PhD
- Independent Director
- 478.79K
- Dr. Stephen L. Mayo, PhD
- Independent Director
- 463.99K
- Elizabeth Barrett
- Independent Director
- 476.43K
- Todd B. Sisitsky
- Independent Director
- --
- John DeYoung
- Independent Director
- --
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data